Intriguingly, PAH patients with GDF2 mutations exhibit reduced plasma levels of both BMP9 and BMP10 and reduced plasma‐derived BMP9/10 endothelial activity.46, 47, 49, 50. The gene discussed is GDF2; the disease is pulmonary arterial hypertension.